Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation |
| |
| Affiliation: | 1. Pediatric Hematology Specialist, University of Health Sciences, Dr Sami Ulus Children’s Hospital, Ankara, Turkey;2. the Pediatric Hematology Unit of the Department of Pediatrics, Medical School of Gazi University, Ankara, Turkey;3. the Pediatric Hematology Unit of the Department of Pediatrics, Medical School of Süleyman Demirel University, Isparta, Turkey;4. the Pediatric Hematology Unit of the Department of Pediatrics, Medical School of Kırıkkale University, Kırıkkale, Turkey;5. Medical School of Gazi University, Ankara, Turkey;6. the Pediatric Hematology Unit of the Department of Pediatrics, Medical School of Başkent University, Ankara, Turkey;7. Pediatric Hematology Specialist, Ankara Dışkapı Child Health and Diseases Hematology Oncology Training And Research Hospital, Ankara, Turkey;1. Toxoplasmosis Research Center, Mazandaran University of Medical Science, Sari, Iran;2. Department of Parasitology, School of Medicine, Mazandaran University of Medical Science, Mazandaran, Sari, Iran;3. Department of Parasitology, School of Medicine, Sari Branch, Islamic AZAD University, Sari, Iran;4. Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;5. Iranian Blood Transfusion Organization, Tehran, Iran;1. SH/Scientific-Hemostasis, Scientific Director and Consultant in Hemostasis and Thrombosis Diagnostics, Franconville, France;2. Hyphen BioMed, Neuville sur Oise, France;3. International Consultancy in Strategic Safety Improvements of Blood-Derived Bioproducts and Suppliers Quality Audit / Inspection, London, UK;1. International Consultancy in Strategic Advice on Safety Improvements of Blood-Derived Bioproducts and Suppliers Quality Audit / Inspection, London, UK;2. Romagna Transplant Network, Hematology Unit, Ravenna-I, Italy;1. Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;2. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;3. Reference Laboratory, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;4. Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran;5. Clinical Research Development Unit, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;1. Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, Greece;2. Department of Biology, Section of Cell Biology and Biophysics, School of Science, National and Kapodistrian University of Athens, Greece |
| |
| Abstract: | ObjectiveTo analyze the impact of donor- and recipient-related factors on Graft-versus-host disease (GVHD) and overall survival of transplantation from matched sibling donors.Methodwe retrospectively analyzed the clinical features of 68 consecutive hematological patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling from 2011 and 2017.ResultsThe incidence of Ⅱ- Ⅳacute GVHD (aGVHD) and chronic GVHD (cGVHD) after transplantation was 13.6 % and 19.7 %, respectively. We also noted the donor and recipient characteristics had no impact on Ⅱ- Ⅳ aGVHD incidence.We found sex mismatch (F-M) did not increase the risk of cGVHD in the model if a female donor was younger than 30 years (P = 1.000), but cGVHD increased if the female donor was ≥30 years (P = 0.002). Recipients≥40 years undergoing HCT from donors ≥30 years were at higher risk for cGVHD (P = 0.021). Development of Ⅱ- Ⅳ aGVHD and cGVHD had no effect on overall survival (P = 0.159, 0.081). Non-remission status at allo-HCT was linked to lower overall survival (P = 0.001).ConclusionThe incidence of cGVHD was higher when male recipients received hematopoietic progenitor cells from female ≥30 years donors, and when older than 40 years recipients received hematopoietic progenitor cells from ≥30 years donors. Patients in non-remission status at allo-HCT was inclined to have lower overall survival. |
| |
| Keywords: | Donor selection Graft versus host disease Allogeneic hematopoietic stem-cell transplantation Overall survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
